Skip to main content

Advertisement

Table 4 Prognostic factor analysis of 39 patients treated with FOLFIRINOX as a second-line treatment

From: Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study

Variable Progression-free survival Overall survival
Median, months (95% CI) Univariate (p value) Multivariate hazard ratio (p value) Median, months (95% CI) Univariate (p value) Multivariate hazard ratio (p value)
Age
 ≤ 60 years 2.3 (0.89–3.71) 0.209 0.565 (0.193) 8.5 (3.39–13.61) 0.514 0.563 (0.209)
 > 60 years 4.83 (2.15–7.51) 8.63 (5.58–11.69)
Sex
 Male 3.3 (1.28–5.32) 0.827   8.5 (4.49–12.51) 0.854  
 Female 3.73 (0–9.46) 8.83 (5.24–12.42)
Extent of disease
 Locally advanced 1.77 (0–4.22) 0.465 1.318 (0.616) 9.67 (7.22–12.12) 0.14 0.379 (0.05)
 Metastatic 4.7 (1.86–7.54) 6.37 (3.56–9.18)
Primary tumor location
 Head 4.7 (0.51–8.89) 0.332 0.711 (0.399) 8.83 (5.55–12.11) 0.569 0.862 (0.719)
 Body or tail 2.9 (1.44–4.36) 7.6 (1.74–13.46)
Liver metastasis
 Yes 6.53 (2.04–11.02) 0.414 0.642 (0.29) 6.37 (2.94–9.8) 0.459 1.052 (0.897)
 No 2.9 (0–6.19) 8.67 (8.18–9.16)
CA19-9 value (U/mL)
 > 10 times of UNL 3.93 (1.52–6.35) 0.972   8.5 (5.51–11.49) 0.653  
 ≤ 10 times of UNL 3.77 (1.17–6.37) 8.83 (2.66–14.99)
  1. CA19-9 carbohydrate antigen 19-9, UNL upper normal limit